Aktis Oncology (AKTS) Gains 2.11% as Investors Eye 200‑Day Support and Peer Performance
Aktis Oncology (AKTS) sees a 2.11% rise to $16.42, trading on a $894M cap and a 200‑day SMA of $21.19. Compare with peers for insight.
- AKTIS ONCOLOGY INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read